U.S. Government Working With BioCryst Inc. (BCRX) To Develop Cure For the Deadly Ebola Virus

BioCryst Pharmaceuticals shares rose as much as 7%, to reach an intraday high of $13.65 Monday, as a positive article by Forbes’ Paul Rodgers on the company’s Ebola drug makes the rounds. According to Rodgers, who cites the respected scientific journal ‘Nature’, BioCryst’s new drug BCX4430 has shown 90% efficacy in animal models by blocking […] View the full post at: U.S. Government Working With BioCryst Inc. (BCRX) To Develop Cure For the Deadly Ebola Virus Related posts: Is Contingent Capital the Cure of the Too Big to Fail Problem? The Deadly Dozen What If the Government Just Prints Money?